MORRISVILLE, N.C., Nov. 19 /PRNewswire/ -- nContact Surgical, Inc. (“nContact”), a leader in the investigation of devices for minimally-invasive treatment for heart conditions, announced that data from a poster was presented at the American Heart Association Scientific Sessions in Orlando. The study demonstrated that the convergent approach, which combines surgical and electrophysiological expertise, appears to be a good strategy to achieve short term success in patients with long standing persistent atrial fibrillation (AF).
“Historically, long standing persistent atrial fibrillation has been the most challenging form of AF to treat,” said Dr. Andrea Natale from the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas. “It is our hope that long-term results from this study and future IDE trials will demonstrate a significant treatment alternative for this AF population.”
nContact is a medical device company founded in 2005 with the company mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris(R) Coagulation System with VisiTrax(R) is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, bi-atrial epicardial lesions on a beating heart.
nContact Surgical, Inc.
